个人科研网厅 | | 帮助
首都医科大学宣武医院知识库
高级检索
当前位置： 首页 > 详情页

Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Yunpeng Yang[1] * ; Bin Wu[2] ; Linian Huang[3] ; Meiqi Shi[4] ; Yunpeng Liu[5] ; Yanqiu Zhao[6] ; Lijun Wang[7] ; Shun Lu[8] ; Gongyan Chen[9] ; Baolan Li[10] ; Conghua Xie[11] ; Jian Fang[12] ; Nong Yang[13] ; Yiping Zhang[14] ; Jiuwei Cui[15] ; Yong Song[16] ; Cuiying Zhang[17] ; Xiaodong Mei[18] ; Bangwei Cao[19] ; Lan Yang[20] ; Ying Cheng[21] ; Kejing Ying[22] ; Tao Sun[23] ; Biyong Ren[24] ; Qitao Yu[25] ; Zijun Liao[26] ; Zhidong Pei[27] ; Mengzhao Wang[28] ; Jianying Zhou[29] ; Shiying Yu[30] ; Guosheng Feng[31] ; Huiping Wan[32] ; Huaqing Wang[33] ; Shegan Gao[34] ; Jinliang Wang[35] ; Guangyu An[36] ; Yi Geng[37] ; Yanxia Ji[38] ; Ying Yuan[39] ; Shenglin Ma[40] ; Zhongyao Jia[41] ; Mu Hu[42] ; Hui Zhou[43] ; Jie Yu[43] ; Xing Sun[43] ; Li Zhang[1,*1] ;
机构： [1]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510000, China [2]Department of Respiratory Medicine, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524002, China [3]Department of Respiratory Medicine, The First Affiliated Hospital of Bengbu Medical College, Bangbu 233000, China [4]Department of Oncology, Jiangsu Cancer Hospital, Nanjing 210009, China [5]Department of Oncology, The First Hospital of China Medical University, Shenyang 110001, China [6]Department of Respiratory Medicine, Henan Cancer Hospital, Zhengzhou 450003, China [7]Department of Tumor radiotherapy, The Second Affiliated Hospital of Xingtai Medical College, Xingtai 054000, China [8]Department of Oncology, Shanghai Chest Hospital, Shanghai 200030, China [9]Department of Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China [10]General Department, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China [11]Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China [12]Department of Oncology, Peking University Cancer Hospital, Beijing 100142, China [13]Department of Pulmonary Gastroenterology, Hunan Cancer Hospital, Changsha 410006, China [14]Department of Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China [15]Department of Oncology, The First Hospital of Jilin University, Changchun 130000, China [16]Department of Respiratory Medicine, General Hospital of Eastern Theater Command, Nanjing 210002, China [17]Department of Oncology, Inner Mongolia People’s Hospital, Hohhot 010017, China [18]Department of Respiratory Medicine, An Hui Provincial Hospital, Hefei 230000, China [19]Department of Oncology, Peking Friendship Hospital, Capital Medical University, Beijing 100050, China [20]Department of Respiratory Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China [21]Department of Oncology, Jilin Cancer Hospital, Changchun 130000, China [22]Department of Respiratory Medicine, Sir Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou 310016, China [23]Department of Internal Medicine, Liaoning Cancer Hospital & Institute, Shenyang 110046, China [24]Department of Respiratory Medicine, Chongqing three Gorges Central Hospital, Chongqing 404000, China [25]Department of Oncology, The Cancer Hospital of Guangxi Zhuang Autonomous Region, Nanning 530000, China [26]Department of Internal Medicine, Shaanxi Provincial Tumor Hospital, Xi’an 710061, China [27]Department of Oncology, Luoyang Central Hospital Affiliated To Zhengzhou University, Luoyang 471009, China [28]Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing 100005, China [29]Department of Respiratory Medicine, The First Affiliated Hospital Zhejiang University, Hangzhou 310003, China [30]Department of Oncology, Tongji Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China [31]Department of Chemotherapy, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning 530000, China [32]Department of Oncology, Jiangxi People’s Hospital, Nanchang 330000, China [33]Department of Oncology, Tianjin People’s Hospital, Tianjin 300121, China [34]Department of Oncology, First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471000, China [35]Department of Oncology, General Hospital of PLA, Beijing 100853, China [36]Department of Oncology, Beijing Chao-Yang Hospital, Beijing 100020, China [37]Department of Oncology, Baoji Central Hospital, Baoji 721008, China [38]Department of Oncology, Handan Central Hospital, Handan 056001, China [39]Department of Oncology, The Second Affiliated Hospital Zhejiang University, Hangzhou 310009, China [40]Department of Oncology, Hangzhou First People’s Hospital, Hangzhou 310002, China [41]Department of Oncology, Linyi People’s Hospital, Linyi 276003, China [42]Department of Chest Surgery, Xuanwu Hospital Capital Medical University, Beijing 100053, China [43]Innovent Biologics, Inc., Suzhou 215123, China
出处：
DOI： 10.21037/tlcr.2019.12.23
ISSN：

关键词： Bevacizumab Biosimilar IBI305 Non-small cell lung cancer (NSCLC) Vascular endothelial growth factor (VEGF)

摘要：
Background: Bevacizumab is a monoclonal antibody (mAb) against vascular endothelial growth factor (VEGF) and used for treatments of various cancers. Due to the high costs of bevacizumab treatments, a biosimilar provides an affordable alternative therapy for cancer patients. Methods: In this randomized, double-blind, multicenter, phase 3 study, locally advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor were enrolled and randomized (1:1) into IBI305 or bevacizumab groups. Patients received 6 cycles of paclitaxel/carboplatin plus IBI305 or bevacizumab 15 mg/kg intravenously followed by IBI305 or bevacizumab 7.5 mg/kg maintenance until disease progression, unacceptable toxicity or death. The primary endpoint was confirmed objective response rate (ORR) by an independent radiological review committee (IRRC) and secondary endpoints included disease control rate (DCR), progression-free survival (PFS), duration of response (DOR), overall survival (OS) and safety. Results: A total of 450 NSCLC patients were enrolled (224 in IBI305 group and 226 in bevacizumab group). ORRs were 44.3% for IBI305 and 46.4% for bevacizumab, and the ORR ratio was 0.95 (90% CI: 0.803 to 1.135), within the predefined equivalence margin of 0.75 to 1.33. No significant difference in PFS (7.64 vs. 7.77 m, P=0.9987) was observed between the 2 groups. Serious adverse events (AEs) occurred in 33.5% (75/224) of patients in the IBI305 group and 37.6% (85/226) in the bevacizumab group. AEs ≥ grade 3 were similar in the IBI305 and bevacizumab groups [84.4% (189/224) vs. 89.8% (203/226), P=0.085]. Conclusions: IBI305 is similar to bevacizumab in terms of efficacy and safety. © Translational lung cancer research. All rights reserved..

基金：
participating study teams for making this study possible and Yuan Fang (Innovent Biologics, Inc., China) for editorial assistance. The study was sponsored by Innovent Biologics, Inc.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
无
最新[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学 3 区 呼吸系统
JCR分区：
出版当年[2017]版：
无
最新[2023]版：
Q1 RESPIRATORY SYSTEM Q2 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者：
第一作者机构： [1]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510000, China
通讯作者：
通讯机构： [1]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510000, China [*1]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510000, China.
推荐引用方式(GB/T 7714)：
Yunpeng Yang,Bin Wu,Linian Huang,et al.Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer[J].TRANSLATIONAL LUNG CANCER RESEARCH.2019,8(6):989-999.doi:10.21037/tlcr.2019.12.23.
APA：
Yunpeng Yang,Bin Wu,Linian Huang,Meiqi Shi,Yunpeng Liu...&Li Zhang.(2019).Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer.TRANSLATIONAL LUNG CANCER RESEARCH,8,(6)
MLA：
Yunpeng Yang,et al."Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer".TRANSLATIONAL LUNG CANCER RESEARCH 8..6(2019):989-999

相关文献

[1]Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer [2]Modified Video-assisted Thoracoscopic Surgery (VATS) Lobectomy for Early-stage Non-small Cell Lung Cancer (NSCLC) [3]Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) [4]Radiofrequency ablation (RFA) for palliative treatment of painful non-small cell lung cancer (NSCLC) rib metastasis: Experience in 12 patients [5]脑外伤后血小板衍生生长因子及血管内皮生长因子对骨折愈合影响的实验研究 [6]电切手术治疗子宫肌病前后子宫内膜VEGF、受体KDR及MVD的表达变化 [7]电切手术前后子宫VEGF、KDR表达及MVD的变化 [8]Interferon regulatory factor 4 (IRF4) is overexpressed in human non-small cell lung cancer (NSCLC) and activates the Notch signaling pathway [9]The effects of recombinant human growth hormone (rHGH) on survival of slender narrow pedicle flap and expressions of vascular endothelial growth factor (VEGF) and classification deteinant 34 (CD34) [10]Expression of vascular endothelial growth factor (VEGF) under hypoxia in placenta with intrahepatic cholestasis of pregnancy and its clinically pathological significance.

资源点击量：16399 今日访问量：0 总访问量：869 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持：重庆聚合科技有限公司 地址：北京市西城区长椿街45号宣武医院